Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | June 02, 2023 | June 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date June 02, 2023 · Filed June 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2033-06-01 | Direct | 18,475 |
Reported balance
After 2023-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-02 · Grant · Acquired 18,475 · Balance 18,475 F1: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 5,037 | $30.60 | $154,132.20 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 7 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,735 F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4865 to $30.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,990 | $30.23 | $60,157.70 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 6 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,772 F5 · price: Represents the closing price of the Company's common shares on March 4, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 20,576 | $3.67 | $75,513.92 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 5 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,288 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · derivative · entry 20 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,288 shares Expires 2022-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F12 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date. F13 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 4,793 | $30.56 | $146,474.08 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 4 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,186 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.53 to $30.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 4,532 | $30.66 | $138,951.12 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 3 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,979 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.49 to $30.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 963 | $31.42 | $30,257.46 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,511 F2 · price: Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 10,288 | $3.67 | $37,756.96 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 20:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 17,557 | $31.33 | $550,060.81 |
DisclosureSEC source: 0001209191-21-064931 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,186 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein Read SEC document |
| May 24, 2021 Filed May 26, 2021 16:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,633 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-21-035911 · doc4.xml · derivative · entry 3 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 22,633 shares Expires 2021-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2011 Vesting Commencement Date. F4 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period. Read SEC document |
| May 24, 2021 Filed May 26, 2021 16:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 5,076 | $19.17 | $97,306.92 |
DisclosureSEC source: 0001209191-21-035911 · doc4.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,743 F2 · price: Represents the closing price of the Company's common shares on May 21, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| May 24, 2021 Filed May 26, 2021 16:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 22,633 | $3.76 | $85,100.08 |
DisclosureSEC source: 0001209191-21-035911 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $20.55 | $0.00 |
DisclosureSEC source: 0001209191-21-020478 · doc4.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Shares · 225,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 16:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | OtherCommon Shares | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048095 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,186 F1 · balance_after: Since the date of the reporting person's last ownership report, he transferred 45,000 common shares to his spouse pursuant to the terms of a settlement agreement dated August 20, 2020 and filed with the Supreme Court of British Columbia in Vancouver, British Columbia on August 21, 2020. The settlement agreement was entered into in connection with the anticipated dissolution of the reporting person's marriage. The reporting person no longer reports as beneficially owned any securities owned by his spouse. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 16:50 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 3,000 | $14.43 | $43,290.00 |
DisclosureSEC source: 0001209191-20-033578 · doc4.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,186 Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:50 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 5,000 | $13.99 | $69,950.00 |
DisclosureSEC source: 0001209191-20-033578 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,186 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:02 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,172 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001209191-20-032628 · doc4.xml · derivative · entry 4 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,172 shares Expires 2020-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:02 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,108 | $14.90 | $16,509.20 |
DisclosureSEC source: 0001209191-20-032628 · doc4.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,186 F2 · price: Represents the closing price of the Company's common shares on May 22, 2020, which was converted to a Canadian dollar amount for purposes of net settlement calculations Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:02 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 6,172 | $3.56 | $21,972.32 |
DisclosureSEC source: 0001209191-20-032628 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:00 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001209191-20-018941 · doc4.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Shares · 280,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 18:14 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 10,395 | $9.51 | $98,856.45 |
DisclosureSEC source: 0001209191-19-050588 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,122 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,345 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · derivative · entry 11 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 12,345 shares Expires 2019-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F6 · derivative.exercise_date: The shares subject to the option fully vested on August 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,259 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · derivative · entry 10 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,259 shares Expires 2019-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F5 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,008 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · derivative · entry 9 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 36,008 shares Expires 2019-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4 · derivative.exercise_date: The shares subject to the option fully vested on May 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 3,692 | $9.44 | $34,852.48 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 6 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,517 F2 · price: Represents the closing price of the Company's common shares on September 16, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 12,345 | $3.38 | $41,726.10 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 5 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 2,769 | $9.44 | $26,139.36 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 4 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,864 F2 · price: Represents the closing price of the Company's common shares on September 16, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 9,259 | $3.07 | $28,425.13 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 3 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 10,769 | $9.44 | $101,659.36 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,374 F2 · price: Represents the closing price of the Company's common shares on September 16, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 36,008 | $3.70 | $133,229.60 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 19:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-19-050148 · doc4.xml · derivative · entry 8 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Shares · 280,000 shares Expires 2029-09-15 F3 · derivative.exercise_date: Vesting over 36 months, in equal amounts, on the last day of each month. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 17:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001171843-18-001913 · formfour.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Shares · 140,000 shares Expires 2028-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 16:52 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,288 | $0.00 Strike: $3.77 | $0.00 |
DisclosureSEC source: 0001171843-18-001956 · f4_pimstone031418.xml · derivative · entry 3 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,288 shares Expires 2018-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F2 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 16:52 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 10,288 | $3.77 | $38,785.76 |
DisclosureSEC source: 0001171843-18-001956 · f4_pimstone031418.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 18:46 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001171843-17-006256 · formfour.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2027-10-22 F1 · derivative.exercise_date: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 18:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | PurchaseCommon Shares | 6,000 | $2.90 | $17,400.00 |
DisclosureSEC source: 0001171843-17-005069 · formfour.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,847 Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001171843-17-001507 · formfour.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Shares · 140,000 shares Expires 2027-03-12 F1 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.